Lauren E Cipriano1,2,3,4,5,6, Shan Liu1,2,3,4,5,6, Kaspar S Shahzada1,2,3,4,5,6, Mark Holodniy1,2,3,4,5,6, Jeremy D Goldhaber-Fiebert1,2,3,4,5,6. 1. Ivey Business School, University of Western Ontario, London, ON, Canada (LEC, KSS). 2. Industrial and Systems Engineering, University of Washington, Seattle, WA (SL). 3. Veterans Affairs Palo Alto Health Care System, Palo Alto, CA (MH). 4. Department of Medicine, Stanford University, Stanford, CA (MH). 5. Division of Infectious Diseases & Geographic Medicine, Stanford University, Stanford, CA (MH). 6. Stanford Health Policy, Center for Health Policy and Center for Primary Care and Outcomes Research, Department of Medicine, Stanford University, Stanford, CA (JDG-F).
Abstract
BACKGROUND: The total cost of treating the 3 million Americans chronically infected with hepatitis C virus (HCV) represents a substantial affordability challenge requiring treatment prioritization. This study compares the health and economic outcomes of alternative treatment prioritization schedules. METHODS: We developed a multiyear HCV treatment budget allocation model to evaluate the tradeoffs of 7 prioritization strategies. We used optimization to identify the priority schedule that maximizes population net monetary benefit (NMB). We compared prioritization schedules in terms of the number of individuals treated, the number of individuals who progress to end-stage liver disease (ESLD), and population total quality-adjusted life years (QALYs). We applied the model to the population of treatment-naive patients with a total annual HCV treatment budget of US$8.6 billion. RESULTS: First-come, first-served (FCFS) treats the fewest people with advanced fibrosis, prevents the fewest cases of ESLD, and gains the fewest QALYs. A schedule developed from optimizing population NMB prioritizes treatment in the first year to patients with moderate to severe fibrosis who are younger than 65 years, followed by older individuals with moderate to severe fibrosis. While this strategy yields the greatest population QALYs, prioritization by disease severity alone prevents more cases of ESLD. Sensitivity analysis indicated that the differences between prioritization schedules are greater when the budget is smaller. A 10% annual treatment price reduction enabled treatment 1 year sooner to several patient subgroups, specifically older patients and those with less severe liver fibrosis. CONCLUSION: In the absence of a sufficient budget to treat all patients, explicit prioritization targeting younger people with more severe disease first provides the greatest health benefits. We provide our spreadsheet model so that decision makers can compare health tradeoffs of different budget levels and various prioritization strategies with inputs tailored to their population.
BACKGROUND: The total cost of treating the 3 million Americans chronically infected with hepatitis C virus (HCV) represents a substantial affordability challenge requiring treatment prioritization. This study compares the health and economic outcomes of alternative treatment prioritization schedules. METHODS: We developed a multiyear HCV treatment budget allocation model to evaluate the tradeoffs of 7 prioritization strategies. We used optimization to identify the priority schedule that maximizes population net monetary benefit (NMB). We compared prioritization schedules in terms of the number of individuals treated, the number of individuals who progress to end-stage liver disease (ESLD), and population total quality-adjusted life years (QALYs). We applied the model to the population of treatment-naive patients with a total annual HCV treatment budget of US$8.6 billion. RESULTS: First-come, first-served (FCFS) treats the fewest people with advanced fibrosis, prevents the fewest cases of ESLD, and gains the fewest QALYs. A schedule developed from optimizing population NMB prioritizes treatment in the first year to patients with moderate to severe fibrosis who are younger than 65 years, followed by older individuals with moderate to severe fibrosis. While this strategy yields the greatest population QALYs, prioritization by disease severity alone prevents more cases of ESLD. Sensitivity analysis indicated that the differences between prioritization schedules are greater when the budget is smaller. A 10% annual treatment price reduction enabled treatment 1 year sooner to several patient subgroups, specifically older patients and those with less severe liver fibrosis. CONCLUSION: In the absence of a sufficient budget to treat all patients, explicit prioritization targeting younger people with more severe disease first provides the greatest health benefits. We provide our spreadsheet model so that decision makers can compare health tradeoffs of different budget levels and various prioritization strategies with inputs tailored to their population.
Entities:
Keywords:
budget impact analysis; cost-effectiveness analysis; hepatitis C virus; population health; resource allocation; treatment prioritization
Authors: Lisa I Backus; Derek B Boothroyd; Barbara R Phillips; Pamela Belperio; James Halloran; Larry A Mole Journal: Clin Gastroenterol Hepatol Date: 2011-03-11 Impact factor: 11.382
Authors: M Michele Manos; Valentina A Shvachko; Rosemary C Murphy; Jean Marie Arduino; Norah J Shire Journal: J Med Virol Date: 2012-11 Impact factor: 2.327
Authors: Carrie McAdam-Marx; Lisa J McGarry; Christopher A Hane; Joseph Biskupiak; Baris Deniz; Diana I Brixner Journal: J Manag Care Pharm Date: 2011-09
Authors: Shan Liu; Lauren E Cipriano; Mark Holodniy; Douglas K Owens; Jeremy D Goldhaber-Fiebert Journal: Ann Intern Med Date: 2012-02-21 Impact factor: 25.391
Authors: Monica L Kasting; Anna R Giuliano; Richard R Reich; Richard G Roetzheim; David R Nelson; Elizabeth Shenkman; Susan T Vadaparampil Journal: Cancer Epidemiol Biomarkers Prev Date: 2018-03-27 Impact factor: 4.254
Authors: Joseph J Amon; Richard S Garfein; Linda Ahdieh-Grant; Gregory L Armstrong; Lawrence J Ouellet; Mary H Latka; David Vlahov; Steffanie A Strathdee; Sharon M Hudson; Peter Kerndt; Don Des Jarlais; Ian T Williams Journal: Clin Infect Dis Date: 2008-06-15 Impact factor: 9.079
Authors: James G Carlucci; Syeda A Farooq; Lindsey Sizemore; Michael Rickles; Brandon Cosley; Leigh McCormack; Carolyn Wester Journal: PLoS One Date: 2017-11-30 Impact factor: 3.240
Authors: Rosa López-Martínez; Andrea Arias-García; Francisco Rodríguez-Algarra; Laura Castellote-Bellés; Ariadna Rando-Segura; Guillermo Tarraso; Elena Vargas-Accarino; Isabel Montserrat-Lloan; Albert Blanco-Grau; Andrea Caballero-Garralda; Roser Ferrer-Costa; Tomas Pumarola-Sunye; Maria Buti-Ferret; Rafael Esteban-Mur; Josep Quer; Ernesto Casis-Saez; Francisco Rodríguez-Frías Journal: J Clin Microbiol Date: 2019-12-23 Impact factor: 5.948